Lv22
146 积分 2024-11-14 加入
Real-world efficacy of enfortumab vedotin in Japanese patients with metastatic urothelial carcinoma stratified by EV-301 trial eligibility: a multicenter Bayesian restricted mean survival time analysis
10小时前
待确认
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
3天前
已完结
More than a little sound
28天前
已关闭
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
1个月前
已完结
Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
1个月前
已完结
Efficacy and safety of PEGylated uricase in healthy adults and patients with hyperuricaemia: A phase I, randomized, double‐blind, dose‐escalation, placebo‐controlled trial
1个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
1个月前
已完结
Design, Synthesis, and Evaluation of Nucleolin-Bridged, MDM2-Recruiting IRAK4 Degraders for the Treatment of Autoimmune Diseases
1个月前
已完结
Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases
1个月前
已完结
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
1个月前
已完结
皖公网安备34019202002308
